Mast Cell Disorders: Protean Manifestations and Treatment Responses
Overview
Overview
Journal
Ann Allergy Asthma Immunol
Specialties
Allergy & Immunology
Pulmonary Medicine
Pulmonary Medicine
Date
2018 Apr 1
PMID
29604336
Citations
1
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Dasilva-Freire N, Mayado A, Teodosio C, Jara-Acevedo M, Alvarez-Twose I, Matito A Int J Mol Sci. 2019; 20(3).
PMID: 30696068 PMC: 6387409. DOI: 10.3390/ijms20030552.
References
1.
Jagdis A, Vadas P
. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014; 113(1):115-6.
DOI: 10.1016/j.anai.2014.05.001.
View
2.
Pardanani A
. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol. 2016; 91(11):1146-1159.
DOI: 10.1002/ajh.24553.
View
3.
Lieberoth S, Thomsen S
. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med. 2015; 2015:903541.
PMC: 4324745.
DOI: 10.1155/2015/903541.
View
4.
Theoharides T, Valent P, Akin C
. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015; 373(2):163-72.
DOI: 10.1056/NEJMra1409760.
View
5.
Akin C
. Mast cell activation syndromes. J Allergy Clin Immunol. 2017; 140(2):349-355.
DOI: 10.1016/j.jaci.2017.06.007.
View